What: Shares of Inovio Pharmaceuticals (INO -9.14%), a clinical-stage biopharmaceutical company primarily focused on developing vaccines, jumped by as much as 11% in early morning trading before pulling back a bit in response to the company's first-quarter earnings results.
So what: Inovio had a productive quarter. Here's a few highlights that investors should be aware of:
- Revenue was $8.1 million, up 55% from the year ago period and compared favorably to the $3.1 million in sales that analysts were expecting. The growth came mostly from an increase in development payments from its DARPA Ebola grant.
- Operating expenses rose 74% to $23.6 million as the company continues to invest heavily in developing its pipeline of product candidates.
- Net loss declined to only $8.0 million for the quarter or $0.11 per share, far lower than the $0.23 loss that Wall Street had projected. The loss would have been much higher but the company booked a $7.4 million investment gain during the period.
- Cash balance at quarter's end was $146.8 million.
- The company completed its acquisition of Bioject Medical Technologies' assets for $5.5 million in cash and stock.
On the clinical side, the company also shared a handful of recent developments with investors:
- Inovio recently met with U.S. and European regulators to discuss the regulatory pathway for VGX-3100 as a potential treatment for cervical dysplasia. The company reported no surprises from the meeting and they still expect to start a phase III trial this year.
- It released data from its phase 1 study of INO-4212, the company's potential Ebola vaccine. Overall, the compound was shown to be safe, tolerable, and generated a strong antibody response in patients.
The combination of better-than-expected financial results mixed with continued progress on its pipeline caused traders to bid up shares today.
Now what: Inovio's stock has been on fire since the start of the year. Shares are already up more than 44% over that time period, which is a massive move, especially when you consider that the biotech sector in general has been out of favor with investors. For example, the iShares Nasdaq Biotechnology ETF (IBB -1.50%), an ETF that owns a broad range of biotechnology stocks, is down more than 22% over that same time period. That makes Inovio's rise look all the more impressive.
Inovio's stock has captured investors' attention thanks to the explosion in media coverage surrounding the Zika virus. Inovio and partner GeneOne Life Science grabbed the spotlight earlier this year when they announced their intention to have a Zika virus vaccine enter clinical at some point in 2016.
With excitement for the stock flying high, investors should keep in mind that even if everything goes perfectly for its Zika virus vaccine, it will still be years before the company could produce any revenue from the compound.
For that reason, I think investors should keep their attention focused on VGX-3110, Inovio's cancer vaccine for treating cervical dysplasia. This compound is much further down the regulatory pathway than the Zika virus vaccine and therefore is several orders of magnitude more important to Inovio's future.
With the company gearing up to put VGX-3110 into phase 3 trials later this year, it won't be long until investors know more about this compound's chances of finding its way to market. That makes Inovio a stock that investors with a strong stomach for risk will want to watch closely.